Skip to main content

comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN

Objective

Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals.
Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to which antibiotic resistance is developing.

To reduce S. aureus disease burden, and antibiotic use associated with it, BELLEROPHON will design, manufacture, and assess in a Phase I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral responses. It is designed to be protective against both MRSA and more sensitive S. aureus strains.

The project will rely on 4 key components:
i) a recently discovered and highly conserved T-cell inducing antigen individually capable of eliciting substantial protection in mouse models;
(ii) a secreted toxin antigen, antibodies against which reduce mortality (Hla);
(iii) an innovative, proprietary and potent pro-immunogenic series of tags (IMX313 series) which can be fused to the antigens;
(iv) the use of viral vectors, including an innovative and proprietary adenoviral vector (ChAdOx1) and/or new ways to use viral vectors to generate protective immunity (MVA mixed with proteins).

We will
i) identify the most protective method of combining these components in a manufacturable and clinically deployable manner;
ii) manufacture and perform initial human studies of the vaccine;
iii) identify additional antigens which might further increase the efficacy of the initial product.

Our approach will contribute clinical safety and immunogenicity data for a novel vaccine strategy targeting one of the key bacterial pathogens in man. It will pave the way for rapid progression to phase II studies, and thence to larger phase II/III studies aiming to reduce infection.

Field of science

  • /natural sciences/biological sciences/microbiology/bacteriology
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/antibiotic resistance

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Address
Wellington Square University Offices
OX1 2JD Oxford
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 022 378
Administrative Contact
Stephen Conway (Dr.)

Participants (3)

IMAXIO SA
France
EU contribution
€ 2 505 885
Address
Rue Saint Roch 5/7
75001 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alexandre Le Vert (Mr.)
PRECLIN BIOSYSTEMS AG
Switzerland
EU contribution
€ 452 000
Address
Route De La Corniche 4
1066 Epalinges
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bettina Ernst (Dr.)
EUROPEAN VACCINE INITIATIVE EWIV
Germany
EU contribution
€ 518 566
Address
Vossstrasse 2 Geb 4040
69115 Heidelberg
Activity type
Research Organisations
Administrative Contact
Sten Larsen (Mr.)